Lipid profile, serum malondialdehyde, superoxide dismutase in chronic kidney diseases and Type 2 diabetes mellitus

The present study was carried out in patients with chronic kidney diseases (CKD) and type 2 diabetes mellitus to evaluate the status of lipid profile, malondialdehyde and superoxide dismutase in total 50 patients of CKD and 50 patients of type 2 diabetes mellitus and 40 healthy individuals were included as control in this study. After 12 hrs, fasting 5 ml. venous blood sample was collected, allowed to clot for half an hour and serum was separated. Lipid profile was measured by using commercially available kit of metro lab auto analyzer. Serum MDA was measured by Wilbur et al method, serum SOD levels were measured by Marklund and Marklund method. The values are expressed as mean ± SD and P value of less than 0.05 was considered as significant. The levels of total cholesterol, LDL cholesterol were decreased where as Triglcerides (TG), VLDL Cholesterol were elevated in CKD patients as compared to control group, though the values were not statistically significant (P>0.05). In type 2 diabetic patients HDL cholesterol significantly decreased (P<0.05) while other parameters of lipid profile were significantly increased (P<0.05) as compared to control group. Serum MDA and SOD were significantly higher (P<0.05) in CKD and type 2 diabetic patients, but not statistically significant as compare to control. In conclusion study shows significant lipoprotein abnormalities in CKD and type 2 diabetes mellitus patients when compared to control. High levels of MDA in CKD and diabetic patients indicating to an increased oxidative stress, the increasing SOD level trying to fight against oxidative stres